Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 6
1997 22
1998 20
1999 26
2000 18
2001 22
2002 17
2003 21
2004 20
2005 15
2006 17
2007 17
2008 12
2009 14
2010 11
2011 10
2012 14
2013 14
2014 14
2015 10
2016 11
2017 14
2018 9
2019 12
2020 11
2021 6
2022 12
2023 4
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

377 results

Results by year

Filters applied: . Clear all
Page 1
Pranlukast: a review of its use in the management of asthma.
Keam SJ, Lyseng-Williamson KA, Goa KL. Keam SJ, et al. Drugs. 2003;63(10):991-1019. doi: 10.2165/00003495-200363100-00005. Drugs. 2003. PMID: 12699401 Review.
Pranlukast was also effective in patients with mild to severe asthma in a clinical practice setting. ...Although Churg-Strauss syndrome has been noted in pranlukast recipients, a direct causal relationship is unlikely. CONCLUSIONS: Pranlukast is a well tolera …
Pranlukast was also effective in patients with mild to severe asthma in a clinical practice setting. ...Although Churg-Strauss syndro …
Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis.
Yelamanchi SD, Arun Kumar ST, Mishra A, Keshava Prasad TS, Surolia A. Yelamanchi SD, et al. Molecules. 2022 Feb 24;27(5):1520. doi: 10.3390/molecules27051520. Molecules. 2022. PMID: 35268621 Free PMC article.
Although extensive research is being carried out at the molecular level in the infected host and pathogen, the identification of suitable drug targets and drugs remains under explored. Pranlukast, an allosteric inhibitor of MtArgJ (Mtb ornithine acetyltransferase) has prev …
Although extensive research is being carried out at the molecular level in the infected host and pathogen, the identification of suitable dr …
Antileukotrienes in upper airway inflammatory diseases.
Cingi C, Muluk NB, Ipci K, Şahin E. Cingi C, et al. Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7. Curr Allergy Asthma Rep. 2015. PMID: 26385352 Review.
By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allerg …
By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlu …
Role of Cysteinyl Leukotrienes in Allergic Rhinitis.
Shirasaki H, Himi T. Shirasaki H, et al. Adv Otorhinolaryngol. 2016;77:40-5. doi: 10.1159/000441871. Epub 2016 Apr 26. Adv Otorhinolaryngol. 2016. PMID: 27115997 Review.
Furthermore, we have revealed that the novel radioactive CysLT1R antagonist [3H]-pranlukast bound specifically to CysLT1R in human inferior turbinates and its binding sites were localized to vascular endothelium and the interstitial cells. ...
Furthermore, we have revealed that the novel radioactive CysLT1R antagonist [3H]-pranlukast bound specifically to CysLT1R in human in …
Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.
Matsuse H, Kohno S. Matsuse H, et al. Expert Opin Pharmacother. 2014 Feb;15(3):353-63. doi: 10.1517/14656566.2014.872241. Epub 2013 Dec 19. Expert Opin Pharmacother. 2014. PMID: 24350802 Review.
AREAS COVERED: Clinical trials as well as basic studies of montelukast and pranlukast in animal models are ongoing. This review report clarifies the current status of these two LTRAs in the treatment of asthma and their future direction. ...
AREAS COVERED: Clinical trials as well as basic studies of montelukast and pranlukast in animal models are ongoing. This review repor …
Asthma pharmacotherapy: an update on leukotriene treatments.
Trinh HKT, Lee SH, Cao TBT, Park HS. Trinh HKT, et al. Expert Rev Respir Med. 2019 Dec;13(12):1169-1178. doi: 10.1080/17476348.2019.1670640. Epub 2019 Sep 26. Expert Rev Respir Med. 2019. PMID: 31544544 Review.
Antagonists against cysteinyl leukotriene receptor (CysLTR) type 1, including montelukast, pranlukast and zafirlukast, have been widely prescribed in clinical practices; however, some clinical trials have shown insignificant responses to LTRAs in adult asthmatics, while so …
Antagonists against cysteinyl leukotriene receptor (CysLTR) type 1, including montelukast, pranlukast and zafirlukast, have been wide …
Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.
Kar M, Altıntoprak N, Muluk NB, Ulusoy S, Bafaqeeh SA, Cingi C. Kar M, et al. Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4111-4117. doi: 10.1007/s00405-016-3983-8. Epub 2016 Mar 16. Eur Arch Otorhinolaryngol. 2016. PMID: 26980339 Review.
By competitive binding to the cysLT1 receptor, LT-receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast block the effects of cySHLTs, improving the symptoms of some chronic respiratory diseases. ...
By competitive binding to the cysLT1 receptor, LT-receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast block th …
Leukotriene Receptor Antagonists and Antiallergy Drugs.
Tamada T, Ichinose M. Tamada T, et al. Handb Exp Pharmacol. 2017;237:153-169. doi: 10.1007/164_2016_72. Handb Exp Pharmacol. 2017. PMID: 27826703 Review.
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asth …
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonis …
Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection.
Kubota J, Takahashi S, Suzuki T, Ito A, Akiyama N, Takahata N. Kubota J, et al. PLoS One. 2022 May 27;17(5):e0269043. doi: 10.1371/journal.pone.0269043. eCollection 2022. PLoS One. 2022. PMID: 35622830 Free PMC article.
The use of respiratory support was significantly lower in infants treated with pranlukast (3.4% [5/147]) than those treated without pranlukast (11.6% [17/147]; P = 0.01). ...CONCLUSIONS: Pranlukast use was associated with a reduced likelihood of requiring res …
The use of respiratory support was significantly lower in infants treated with pranlukast (3.4% [5/147]) than those treated without …
Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.
Velázquez-Quesada I, Ruiz-Moreno AJ, Casique-Aguirre D, Aguirre-Alvarado C, Cortés-Mendoza F, de la Fuente-Granada M, García-Pérez C, Pérez-Tapia SM, González-Arenas A, Segura-Cabrera A, Velasco-Velázquez MA. Velázquez-Quesada I, et al. Drug Des Devel Ther. 2020 May 12;14:1799-1811. doi: 10.2147/DDDT.S247730. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32494122 Free PMC article.
Pranlukast decreased the clonogenicity of breast cancer cells on mammosphere formation assay but had no impact on the viability of bulk tumor cells. ...CONCLUSION: Our results support the function of pranlukast as a CD49f antagonist that reduces the CSC population i …
Pranlukast decreased the clonogenicity of breast cancer cells on mammosphere formation assay but had no impact on the viability of bu …
377 results